EP3065770A1 - COMBINATION THERAPY FOR TREATING CANCER WITH A POXVIRUS EXPRESSING A TUMOR ANTIGEN AND AN ANTAGONIST AND/OR AGONIST OF AN IMMUNE CHECKPOINT INHIBITOR